British American Tobacco (BTI) | NYSE | Analysis as of August 26, 2026 | Reconciled price $57.65
On July 30, British American Tobacco (BTI) raised its full-year earnings outlook, accelerated New Category revenue to 18.0% at constant currency, and lifted net cash from operating activities 47.3% to GBP 3.4 billion. The stock fell roughly 6% over the following month and 13% over three. That gap is what I want to work on. "Good news, stock fell, therefore buy" is lazy and usually wrong, so let's ask a better question instead.
How much decline is already priced into $57.65? Work backward from the enterprise value and the answer comes out lower than I expected. I ran that calculation before writing anything else here.
What the business is, in plain terms
BAT sells nicotine in four formats: cigarettes, vapor, heated products, and modern oral pouches. Cigarettes still fund everything.
The pouch and vapor businesses carry the growth. The whole debate is whether that second group scales fast enough to matter before the first group shrinks too far.
At the half-year mark the split looked like this. Smokeless products reached 19.8% of group revenue, a gain of 1.6 points on full-year 2025. New Categories specifically ran GBP 1,928 million of the GBP 12,235 million total, so about 15.8%, growing 18.0% at constant currency. Modern oral, now the largest of those categories by revenue, grew 65.9% and took 39.2% volume share in BAT's top markets, an 8.4 point gain on the year.
Profitability moved with it. Contribution from those categories rose 54.7% to GBP 257 million, with contribution margin improving 3.3 points to 13.3%.
Regionally the picture is lopsided, and I'd rather you see that than have me average it away. American revenue grew 8.5%, and adjusted operating profit there grew 10.1%.
Asia-Pacific, Middle East and Africa went the other way. Revenue fell 6.3% and adjusted profit from that region fell 16.5%. That second figure is worse than the revenue decline implies, and it is the softest spot in the results.
The chart says the market hasn't agreed yet
I'll be honest, the technical setup is not a reason to buy this. It's a reason to buy it in pieces.
Price is near $57.60 after a bounce off the lower Bollinger band around $55. It sits below both the 50-day average near $59.7 and the 200-day near $58.1, and MACD is below its signal line with both under zero.
On-balance volume has been grinding lower since June. The bounce hasn't been confirmed by the kind of accumulation I'd want to see.
Two things on that chart are constructive. The RSI panel flags a divergence through mid-August, with the oscillator putting in higher lows while price made lower lows, and the MACD histogram has compressed back toward the zero line. Both are early signals and I wouldn't call either a confirmation yet.
So my read is that this is a value entry with no momentum support. Do you need the trend agreeing with you before you commit? Then wait for a close above roughly $59.50 with the histogram crossing positive. You'll pay a few percent more for the comfort, and that's a perfectly legitimate trade to make.
The cost program almost nobody is modelling
Now for something that didn't get much attention and probably should have.
On June 29, BAT announced a restructuring that removes about 5,500 roles and transfers roughly 3,500 more to third-party partners. Combined, that touches around 9,000 people, close to a fifth of a global workforce of roughly 47,000, and it excludes the United States. Management is targeting some GBP 600 million of additional annualized savings by the end of 2028, with roughly GBP 500 million of that landing by 2027.
Sign in to leave a comment and join the discussion.
Sign Up Free